Large-scale testing (Phase 3)Study completedNCT04109066
What this trial is testing
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Who this might be right for
Breast Cancer
Bristol-Myers Squibb 521